LD-2 disclosure · 2nd Quarter - Report
ALNYLAM PHARMACEUTICALS
Client
- Description
- Biopharmaceutical company
- Location
- Massachusetts · United States of America
Registrant
- Description
- Consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Access to DME-infused drugs in the home. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for S.476 Maintaining Investments in New Innovation Act
LobbyistsJOHN MCMANUS · ALANNA TEMME · ms LAWREN D GEER
Covered position (JOHN MCMANUS): Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas
Covered position (ALANNA TEMME): LD, Rep. Jon Porter
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
LobbyistsJOHN MCMANUS · ALANNA TEMME
TargetedSENATE · HOUSE OF REPRESENTATIVES